{"id":43679,"date":"2025-10-17T14:57:26","date_gmt":"2025-10-17T06:57:26","guid":{"rendered":"https:\/\/flcube.com\/?p=43679"},"modified":"2025-10-17T14:57:27","modified_gmt":"2025-10-17T06:57:27","slug":"cstones-sugemalimab-receives-positive-ema-opinion-for-stage-iii-nsclc","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=43679","title":{"rendered":"CStone\u2019s Sugemalimab Receives Positive EMA Opinion for Stage\u202fIII NSCLC"},"content":{"rendered":"\n<p><strong>CStone Pharmaceuticals<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/2616:HKG\">HKG: 2616<\/a>) announced today that the European Medicines Agency\u2019s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion, recommending approval of <strong>sugemalimab monotherapy<\/strong> for adult patients with unresectable Stage\u202fIII non\u2011small cell lung cancer (NSCLC) who are PD\u2011L1\u202f\u2265\u202f1\u202f%, lack EGFR\u2011sensitizing mutations or ALK\/ROS1 aberrations, and whose disease has not progressed after platinum\u2011based chemoradiotherapy (CRT).<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-key-highlights\">Key Highlights<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Feature<\/th><th>Details<\/th><\/tr><\/thead><tbody><tr><td><strong>Indication<\/strong><\/td><td>Adult unresectable Stage\u202fIII NSCLC with PD\u2011L1\u202f\u2265\u202f1\u202f% (no EGFR\u2011sensitizing, ALK, ROS1 aberrations) post\u2011platinum CRT<\/td><\/tr><tr><td><strong>Regulatory Status<\/strong><\/td><td>Positive EMA CHMP opinion \u2192 recommended approval<\/td><\/tr><tr><td><strong>Development Platform<\/strong><\/td><td>OmniRat transgenic animal platform \u2013 one\u2011stop generation of fully human IgG4 anti\u2011PD\u2011L1<\/td><\/tr><tr><td><strong>Existing Approvals<\/strong><\/td><td>EU &amp; UK: sugemalimab + platinum chemo for first\u2011line metastatic NSCLC (no EGFR\/ALK\/ROS1\/RET aberrations)<\/td><\/tr><tr><td><strong>Clinical Advantage<\/strong><\/td><td>Fully human IgG4 reduces immunogenicity &amp; toxicity risk<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-about-sugemalimab\">About Sugemalimab<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism<\/strong> \u2013 Fully human, full\u2011length IgG4 monoclonal antibody targeting PD\u2011L1, the closest to native human antibody structure.<\/li>\n\n\n\n<li><strong>Platform Advantage<\/strong> \u2013 OmniRat technology enables rapid, scalable production of fully human antibodies, potentially lowering immunogenicity and related toxicity.<\/li>\n\n\n\n<li><strong>Clinical Impact<\/strong> \u2013 In Stage\u202fIII NSCLC, sugemalimab monotherapy offers a new therapeutic option for patients who have exhausted platinum\u2011based CRT and lack actionable driver mutations.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-implications-for-cstone\">Strategic Implications for CStone<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Market Expansion<\/strong> \u2013 Positive EMA opinion positions CStone for rapid entry into the European market for a high\u2011need NSCLC indication.<\/li>\n\n\n\n<li><strong>Portfolio Strengthening<\/strong> \u2013 Adds a monotherapy asset to CStone\u2019s immuno\u2011oncology pipeline, complementing existing combination approvals.<\/li>\n\n\n\n<li><strong>Global Growth Trajectory<\/strong> \u2013 Aligns with CStone\u2019s strategy to leverage OmniRat\u2011derived therapies across oncology indications worldwide.<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This release contains forward\u2011looking statements that involve risks and uncertainties. Actual results may differ materially.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2025101700048_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2025101700048_c.\"><\/object><a id=\"wp-block-file--media-bb07aa34-215f-4237-8408-63d877a33907\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2025101700048_c.pdf\">2025101700048_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2025101700048_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-bb07aa34-215f-4237-8408-63d877a33907\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>CStone Pharmaceuticals (HKG: 2616) announced today that the European Medicines Agency\u2019s (EMA) Committee for Medicinal&#8230;<\/p>\n","protected":false},"author":1,"featured_media":43682,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[16,188,856,18],"class_list":["post-43679","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-cancer","tag-cstone-pharmaceuticals","tag-hkg-2616","tag-pd-1-l1"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>CStone\u2019s Sugemalimab Receives Positive EMA Opinion for Stage\u202fIII NSCLC - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"CStone Pharmaceuticals (HKG: 2616) announced today that the European Medicines Agency\u2019s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion, recommending approval of sugemalimab monotherapy for adult patients with unresectable Stage\u202fIII non\u2011small cell lung cancer (NSCLC) who are PD\u2011L1\u202f\u2265\u202f1\u202f%, lack EGFR\u2011sensitizing mutations or ALK\/ROS1 aberrations, and whose disease has not progressed after platinum\u2011based chemoradiotherapy (CRT).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=43679\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CStone\u2019s Sugemalimab Receives Positive EMA Opinion for Stage\u202fIII NSCLC\" \/>\n<meta property=\"og:description\" content=\"CStone Pharmaceuticals (HKG: 2616) announced today that the European Medicines Agency\u2019s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion, recommending approval of sugemalimab monotherapy for adult patients with unresectable Stage\u202fIII non\u2011small cell lung cancer (NSCLC) who are PD\u2011L1\u202f\u2265\u202f1\u202f%, lack EGFR\u2011sensitizing mutations or ALK\/ROS1 aberrations, and whose disease has not progressed after platinum\u2011based chemoradiotherapy (CRT).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=43679\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-17T06:57:26+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-10-17T06:57:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1707.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43679#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43679\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"CStone\u2019s Sugemalimab Receives Positive EMA Opinion for Stage\u202fIII NSCLC\",\"datePublished\":\"2025-10-17T06:57:26+00:00\",\"dateModified\":\"2025-10-17T06:57:27+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43679\"},\"wordCount\":298,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43679#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/1707.webp\",\"keywords\":[\"Cancer\",\"CStone Pharmaceuticals\",\"HKG: 2616\",\"PD-1\\\/L1\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=43679#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43679\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=43679\",\"name\":\"CStone\u2019s Sugemalimab Receives Positive EMA Opinion for Stage\u202fIII NSCLC - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43679#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43679#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/1707.webp\",\"datePublished\":\"2025-10-17T06:57:26+00:00\",\"dateModified\":\"2025-10-17T06:57:27+00:00\",\"description\":\"CStone Pharmaceuticals (HKG: 2616) announced today that the European Medicines Agency\u2019s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion, recommending approval of sugemalimab monotherapy for adult patients with unresectable Stage\u202fIII non\u2011small cell lung cancer (NSCLC) who are PD\u2011L1\u202f\u2265\u202f1\u202f%, lack EGFR\u2011sensitizing mutations or ALK\\\/ROS1 aberrations, and whose disease has not progressed after platinum\u2011based chemoradiotherapy (CRT).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43679#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=43679\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43679#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/1707.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/1707.webp\",\"width\":1080,\"height\":608,\"caption\":\"CStone\u2019s Sugemalimab Receives Positive EMA Opinion for Stage\u202fIII NSCLC\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43679#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CStone\u2019s Sugemalimab Receives Positive EMA Opinion for Stage\u202fIII NSCLC\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"CStone\u2019s Sugemalimab Receives Positive EMA Opinion for Stage\u202fIII NSCLC - Insight, China&#039;s Pharmaceutical Industry","description":"CStone Pharmaceuticals (HKG: 2616) announced today that the European Medicines Agency\u2019s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion, recommending approval of sugemalimab monotherapy for adult patients with unresectable Stage\u202fIII non\u2011small cell lung cancer (NSCLC) who are PD\u2011L1\u202f\u2265\u202f1\u202f%, lack EGFR\u2011sensitizing mutations or ALK\/ROS1 aberrations, and whose disease has not progressed after platinum\u2011based chemoradiotherapy (CRT).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=43679","og_locale":"en_US","og_type":"article","og_title":"CStone\u2019s Sugemalimab Receives Positive EMA Opinion for Stage\u202fIII NSCLC","og_description":"CStone Pharmaceuticals (HKG: 2616) announced today that the European Medicines Agency\u2019s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion, recommending approval of sugemalimab monotherapy for adult patients with unresectable Stage\u202fIII non\u2011small cell lung cancer (NSCLC) who are PD\u2011L1\u202f\u2265\u202f1\u202f%, lack EGFR\u2011sensitizing mutations or ALK\/ROS1 aberrations, and whose disease has not progressed after platinum\u2011based chemoradiotherapy (CRT).","og_url":"https:\/\/flcube.com\/?p=43679","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-10-17T06:57:26+00:00","article_modified_time":"2025-10-17T06:57:27+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1707.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=43679#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=43679"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"CStone\u2019s Sugemalimab Receives Positive EMA Opinion for Stage\u202fIII NSCLC","datePublished":"2025-10-17T06:57:26+00:00","dateModified":"2025-10-17T06:57:27+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=43679"},"wordCount":298,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=43679#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1707.webp","keywords":["Cancer","CStone Pharmaceuticals","HKG: 2616","PD-1\/L1"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=43679#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=43679","url":"https:\/\/flcube.com\/?p=43679","name":"CStone\u2019s Sugemalimab Receives Positive EMA Opinion for Stage\u202fIII NSCLC - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=43679#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=43679#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1707.webp","datePublished":"2025-10-17T06:57:26+00:00","dateModified":"2025-10-17T06:57:27+00:00","description":"CStone Pharmaceuticals (HKG: 2616) announced today that the European Medicines Agency\u2019s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion, recommending approval of sugemalimab monotherapy for adult patients with unresectable Stage\u202fIII non\u2011small cell lung cancer (NSCLC) who are PD\u2011L1\u202f\u2265\u202f1\u202f%, lack EGFR\u2011sensitizing mutations or ALK\/ROS1 aberrations, and whose disease has not progressed after platinum\u2011based chemoradiotherapy (CRT).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=43679#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=43679"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=43679#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1707.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1707.webp","width":1080,"height":608,"caption":"CStone\u2019s Sugemalimab Receives Positive EMA Opinion for Stage\u202fIII NSCLC"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=43679#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"CStone\u2019s Sugemalimab Receives Positive EMA Opinion for Stage\u202fIII NSCLC"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1707.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/43679","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=43679"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/43679\/revisions"}],"predecessor-version":[{"id":43683,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/43679\/revisions\/43683"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/43682"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=43679"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=43679"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=43679"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}